Report Overview

The Europe lung cancer therapeutic market size stood at around USD 1.67 billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Netherlands has the third highest cancer rate in Europe. Amongst the different types of cancer, lung cancer was the top cause of death and disability combined in 2019 in Netherlands. It has been seen that incidence is greater above the age of 60; however, younger females are increasingly being impacted. Diagnosis usually occurs after metastasis, which decreases the chances of survival. The Dutch Government hopes to combat this rise with anti-smoking campaigns and is considering the implementation of lung cancer screening.

In 2017, expenditure on care for lung cancer amounted to a total of 456.7 million euros. This corresponds to 7.8% of the total expenditure on health care for new formation and 0.52% of the total expenditure on health care in the Netherlands. Of the health care expenditure for lung cancer, 398 million euros (87%) went to hospital care and medical specialist care.



Market Drivers

The market is majorly driven by the increasing burden of lung cancer in Netherlands. According to the Netherlands Cancer Registry (IKNL), the number of lung cancer cases were 23,966 in 2019 and 24,927 in 2020. The percentage increase in cases from 2019 to 2020, for females, was 1.3% as opposed to 0.4% in males. This is attributed to high numbers of female smokers. According to the Integrated Cancer Centre of Netherlands (IKNL), such high incidence of lung cancer is also caused due to lifestyle and genetic factors.

Another market driver is the increase in diagnosis and awareness.